Wordt geladen...
Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing–remitting multip...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3593763/ https://ncbi.nlm.nih.gov/pubmed/23494602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S32687 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|